| Recruiting | Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis NCT07318129 | Glostrup University Hospital, Copenhagen | N/A |
| Recruiting | A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis NCT07321093 | Biocad | Phase 3 |
| Not Yet Recruiting | A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy I NCT07189325 | University Hospital, Montpellier | Phase 3 |
| Active Not Recruiting | "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" NCT06800404 | Hope Biosciences Research Foundation | Phase 2 |
| Recruiting | Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) NCT06700343 | Amgen | Phase 3 |
| Not Yet Recruiting | Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and NCT06663189 | University Hospital, Strasbourg, France | Phase 3 |
| Recruiting | ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS NCT06733922 | Novartis Pharmaceuticals | Phase 4 |
| Active Not Recruiting | The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multip NCT07497126 | Antalya Training and Research Hospital | — |
| Active Not Recruiting | Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis NCT06430671 | Cellerys AG | Phase 1 |
| Active Not Recruiting | A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) P NCT05811416 | Bristol-Myers Squibb | — |
| Withdrawn | Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab NCT05172466 | Icahn School of Medicine at Mount Sinai | N/A |
| Unknown | Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical S NCT05245344 | Neuromed IRCCS | — |
| Completed | A Study for Tysabri Participant Preference NCT05304520 | Biogen | — |
| Completed | Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® NCT04115488 | Polpharma Biologics S.A. | Phase 3 |
| Active Not Recruiting | MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) NCT03846219 | Immunic AG | Phase 2 |
| Recruiting | Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis NCT05177523 | University Hospital, Basel, Switzerland | — |
| Completed | Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Scle NCT05242133 | Cinnagen | Phase 3 |
| Terminated | Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab NCT02881567 | Biogen | Phase 3 |
| Completed | Plegridy Satisfaction Study in Participants NCT02587065 | Biogen | Phase 4 |
| Withdrawn | Brimonidine Tartrate for the Treatment of Injection Related Erythema NCT02568111 | Biogen | Phase 4 |
| Completed | Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multip NCT02035514 | Germans Trias i Pujol Hospital | Phase 1 / Phase 2 |
| Completed | Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Inje NCT01738347 | GE Healthcare | Phase 1 |
| Completed | A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® NCT01705236 | Novartis Pharmaceuticals | Phase 4 |
| Terminated | MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone NCT01633112 | Novartis Pharmaceuticals | Phase 3 |
| Terminated | Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natal NCT01499667 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Tre NCT01125475 | Merck KGaA, Darmstadt, Germany | — |
| Completed | A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambu NCT00871780 | Biogen | Phase 4 |
| Completed | Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence NCT00787657 | Bayer | — |
| Completed | Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion NCT01235455 | Bayer | — |
| Completed | RNF and Betaseron® Tolerability Study NCT00428584 | EMD Serono | Phase 3 |